Zacks Research Has Negative Forecast for TEVA Q2 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Investment analysts at Zacks Research dropped their Q2 2026 earnings per share (EPS) estimates for shares of Teva Pharmaceutical Industries in a research report issued to clients and investors on Monday, April 28th. Zacks Research analyst R. Department now expects that the company will earn $0.60 per share for the quarter, down from their prior estimate of $0.62. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q3 2026 earnings at $0.78 EPS, Q4 2026 earnings at $0.70 EPS, FY2026 earnings at $2.56 EPS, Q1 2027 earnings at $0.60 EPS and FY2027 earnings at $2.77 EPS.

TEVA has been the subject of several other reports. Piper Sandler lifted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. UBS Group cut their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. Finally, Barclays dropped their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Down 0.8 %

Teva Pharmaceutical Industries stock traded down $0.13 on Thursday, hitting $16.27. 13,264,415 shares of the stock traded hands, compared to its average volume of 10,029,495. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The business's fifty day simple moving average is $15.10 and its 200 day simple moving average is $17.48. The firm has a market cap of $18.44 billion, a P/E ratio of -11.22, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries has a 1 year low of $12.47 and a 1 year high of $22.80.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of TEVA. Y Intercept Hong Kong Ltd raised its holdings in Teva Pharmaceutical Industries by 48.6% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 193,387 shares of the company's stock worth $2,972,000 after purchasing an additional 63,241 shares during the period. Financial Sense Advisors Inc. increased its stake in Teva Pharmaceutical Industries by 63.5% in the 1st quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company's stock worth $6,231,000 after buying an additional 157,421 shares in the last quarter. Allianz Asset Management GmbH raised its holdings in Teva Pharmaceutical Industries by 12.2% during the first quarter. Allianz Asset Management GmbH now owns 678,992 shares of the company's stock valued at $10,436,000 after acquiring an additional 73,601 shares during the period. Teachers Retirement System of The State of Kentucky lifted its position in shares of Teva Pharmaceutical Industries by 10.8% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 1,894,100 shares of the company's stock valued at $29,112,000 after acquiring an additional 184,100 shares in the last quarter. Finally, Kestra Private Wealth Services LLC boosted its stake in shares of Teva Pharmaceutical Industries by 6.6% in the first quarter. Kestra Private Wealth Services LLC now owns 33,598 shares of the company's stock worth $516,000 after acquiring an additional 2,072 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.